Account Navigation

Account Navigation

Currency - All prices are in AUD

Currency - All prices are in AUD
EpiCypher

Press Releases

EpiCypher  is a company on the move. We are early adopters of new epigenetic technologies. We are developers in our own right of new, improved epigenetic screen services. We are the first in many areas epigenetics research and will continue to be the first on many forefronts.

We hope you’ll keep up with us by staying up-to-date on our latest company news, published here regularly. 

EpiCypher Launches SNAP-ChIP™ Product Family: Now Enabling Normalized Chromatin IP Experiments

Download PDF

FOR IMMEDIATE RELEASE

EpiCypher Launches SNAP-ChIP Product Family: Now Enabling Normalized Chromatin IP Experiments

Research Triangle Park, NC - 22 September 2017 – EpiCypher, Inc. has released SNAP-ChIP (Sample Normalization and Antibody Profiling for Chromatin Immunoprecipitation), a breakthrough product family that will dramatically improve researchers’ ability to normalize ChIP experiments. SNAP-ChIP utilizes EpiCypher’s proprietary DNA barcoded recombinant designer nucleosomes (dNucs) as next-generation spike-ins for ChIP. With SNAP-ChIP, researchers now have the ability to both normalize samples across experiments (enabling broad collaboration throughout the scientific community, an the generate detailed data pertaining to antibody specificity and cross-reactivity.

The first offering in the SNAP-ChIP family, the SNAP-ChIP K-MetStat panel (lysine-methylation status panel), is comprised of 16 uniquely modified dNucs carrying disease-relevant lysine methylation modifications on histones H3 and H4. Each modification site in this pool (H3K4, H3K9, H3K27, H3K36, H4K20) is represented by all lysine methylation states (i.e. me0, me1, me2, and me3). “For the first time, scientists can both monitor technical variability and measure antibody specificity in the same experiment. This has not been possible with any other spike-in product or approach currently available,” states EpiCypher’s Chief Scientific Officer, Michael Keogh, PhD. Keogh further adds “The beauty of the SNAP-ChIP product line is that it fits seamlessly into existing ChIP workflows, allowing the epigenetics community immediate access to this breakthrough. In fact, we have already contracted with a number of antibody development companies to use our SNAP-ChIP K-MetStat Panel to directly analyze the specificity of antibodies in their portfolios in a ChIP setting.”

Numerous additional modification-specific SNAP-ChIP dNuc panels are currently in development (e.g. arginine methylation, lysine acylation, etc.) and are slated for release in early 2018.

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide. EpiCypher manufactures and sells recombinant “designer” modified nucleosomes (dNucs), including the EpiDyne™ family of substrates for nucleosome remodeling assays, as well as recombinant histone binding proteins, peptides and antibodies, and offers a broad range of custom substrate manufacturing and assay development services.

For more information about SNAP-ChIP, visit EpiCypher.com/SNAP-ChIP
For more information about EpiCypher, visit EpiCypher.com

Media Contact:
Jim Bone, PhD
President
EpiCypher, Inc.
434-996-8107
jim@epicypher.com

EpiCypher Named Best University Startup by United States Congress

Download PDF

FOR IMMEDIATE RELEASE

EpiCypher Named Best University Startup by United States Congress

Research Triangle Park, NC - 7 September 2016.  EpiCypher today announced its designation as Best University Startup by the National Council of Entrepreneurial Tech Transfer (NCET2), a group designated by the 114th United States Congress.  EpiCypher will present to US Congress, investors and corporate partners at the inaugural University Startups “Demo Day” at the National Press Club in Washington, DC on September 20, 2016.

There are over 4,800 active university start-ups in the United States today.  Those recognized as the Best University Startups 2016 are among the most exciting early-stage companies originating from the country's top tier universities.

"We are delighted and honored to be named Best University StartUp at the inaugural Demo Day 2016 in Washington DC. EpiCypher has been built from the dedication and focus of our employees & Founders, support from our customers, and funding from Americas’ Seed Fund, the NIH SBIR program,” said Jim Bone, President, EpiCypher. “Our future is bright for both job creation and the rapid launch of new products and services. The fusion of these key elements enable us to realize our ultimate mission of saving human lives.

EpiCypher is a spinout from The University of North Carolina at Chapel Hill.  Scientific Founders Drs. Brian Strahl, Vice-Chair (Department of Biochemistry & Biophysics at UNC-CH), Mark Bedford, Professor (MD Anderson Cancer Center), and Or Gozani, Professor (Stanford University) established the original scientific vision for the Company that remains today. "To lead the world in the 21st Century, our nation must have a sustained commitment to education, scientific research, and startups," says Tony Stanco, NCET2 executive director, "and American universities are uniquely positioned to deliver on all three to ensure the U.S. continues to lead socially and economically in this century, as it did in the last."

EpiCypher Snaphot:

  • 85 blue-chip customers
  • 18 full-time employees; 80% with advanced degrees
  • The only UNC-Chapel Hill spinout that is cash-flow positive (circa 2012)
  • Doubled revenue annually for the past 3 years

 

About EpiCypher.  EpiCypher is pioneering the science of epigenetics. Epigenetics is the conjunction of ‘epi’, Latin for above, and genetics.  Epigenetics is an essential dimension of personalized medicine, representing additional biological coding beyond genetics that regulates protein expression.   EpiCypher has brought necessary products to market, including the first biochemically pure recombinant nucleosome and the first industry-developed designer nucleosomes.  In addition, EpiCypher is developing the first reliable epigenetics biomarker measurement system for use in research and clinical applications.  EpiCypher has over 85 blue-chip customers, 18 people, and is cash-flow positive.  For more information visit epicypher.com.

Media Contact: Jim Bone 855-374-2461

EpiCypher Announces Key Appointments to Bolster Sales and Product Development

Download PDF

FOR IMMEDIATE RELEASE

EpiCypher Announces Key Appointments to Bolster Sales and Product Development Expansion of management team deepens scientific capability, client service and support.

Research Triangle Park, NC – 16 February 2016 – EpiCypher Inc., a global provider of epigenetics research products and services, today announced the appointment of two talented individuals to its management team in response to new R&D directives and an increased share of the epigenetics products market.

Danielle Mahon.  Director, Scientific Sales Ms. Mahon brings 21 years of successful sales experience to EpiCypher including the last 10 years in the life science arena managing capital equipment and consumable sales in pharmaceutical, biotechnology and academic settings. During this time Ms. Mahon worked for industry leaders including Eppendorf, Mettler Toledo and ThermoFisher Scientific. She has a strong track record with key account development and management. She holds a Bachelors of Science in Management from Rutgers University.

Michael-Christopher Keogh, Ph.D. Director, Markets and Application Development Dr. Keogh earned his PhD in Molecular Immunology from Imperial College London and completed postdoctoral studies in the Thrombosis Research Institute (London) and with Dr. Steve Buratowski at Harvard Medical School. Prior to joining EpiCypher he was a Principal Investigator in the Department of Cell Biology at Albert Einstein College of Medicine. His work has focused on many key oncology research areas including cell-cycle regulation, DNA repair, epigenetics, gene expression and genetic networks.

“The addition of these highly talented and experienced individuals to the EpiCypher team deepens our capability to deliver innovative and practical solutions to our customer base.  Danielle brings world-class success in delivering global customer success and distributor engagement.  In her role, Danielle will develop and implement our commercial strategy,” said Jim Bone, President and co-founder of EpiCypher.  “Michael brings exceptional scientific experience with an outstanding publication track record.  His external focus on application development will significantly benefit our customer base.  In his role, Michael will bring forward EpiCypher’s deep scientific expertise in driving development and adoption of our innovative product portfolio”. 

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide. EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services.

For more information about EpiCypher, visit EpiCypher.com.

Media Contact: Jim Bone, President EpiCypher, Inc. 855-374-2461

EpiCypher Expands Global Distribution Network

Download PDF

FOR IMMEDIATE RELEASE

EpiCypher Expands Global Distribution Network Company responds to increased global demand for products and services.

Research Triangle Park, NC  - 16 February 2016 - EpiCypher Inc. added five strategic distributors in 2015 responding to increased global demand for the Company’s products and services. A total of 16 companies now represent EpiCypher outside of the United States, including nine in Europe. 

EpiCypher announced the following distributors after the significant training and support from EpiCypher to enable success in their local markets.

North America: MJS BioLynx, Inc - Brockville, Ontario, Canada (biolynx.ca)

Asia: ABclonal Biotechnology Co., Ltd - Wuhan, Hubei, P.R.China (abclonal.com) Bioinborn Scientific, Inc - Wuhan City, China P.C. (bioinborn.com) Cistron Biolab - Kattupakkam, Chennai, India (cistronbiolab.com) KOMA BIOTECH - Seoul, South Korea (komabiotech.com)

“The addition of these highly reputable companies to the EpiCypher distributor portfolio will broaden our sales capacity in established international markets”, said Danielle Mahon, Director of Scientific Sales, EpiCypher. “The end-user will benefit from local customer service and expedited shipping of our products.”

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide. EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services.

For more information about EpiCypher, visit EpiCypher.com.

Media Contact: Jim Bone, President EpiCypher, Inc. 855-374-2461

EpiCypher Announces EpiCypher2016 as Major Epigenetics Conference

Download PDF

FOR IMMEDIATE RELEASE

EpiCypher Announces EpiCypher2016 as Major Epigenetics Conference PerkinElmer among sponsors of EpiCypher 2016.

Research Triangle Park, NC - 10 February 2016 – EpiCypher, Inc. has announced EpiCypher2016, a conference focused on Biological and Chemical Frontiers in Epigenetics, to be held April 20-23 in San Juan, Puerto Rico. The conference is being organized by Drs. Brian Strahl, University of North Carolina at Chapel Hill; Or Gozani, Stanford University; and Mark Bedford, Univ. Texas MD Anderson Cancer Center.

The four-day conference at the luxury oceanfront Caribe Hilton in San Juan will highlight recent breakthroughs in epigenetics and chromatin research and will foster the collaboration and exchange of scientific expertise and knowledge in one of the most vibrant areas of life sciences. Through scientific presentations, a wide spectrum of topics in epigenetics and chromatin biology will be explored. The conference has over 25 confirmed speakers with a lineup of luminaries and thought leaders from industry and academic centers. PerkinElmer, Inc. is a sponsor for the event.

“EpiCypher2016 represents a significant commitment to the field and the thought leaders that are shaping the future of epigenetics. We’re delighted to have PerkinElmer as part of this inaugural event in light of our recent collaboration yielding a panel of bromodomain binding assays utilizing their highly sensitive AlphaLISA® detection technology.” said Jim Bone, President and co-founder of EpiCypher. “We look forward to noteworthy announcements and scientific findings from EpiCypher2016.”

EpiCypher2016 will feature keynote addresses by Dr. C. David Allis and Dr. Yang Shi. Dr. Allis is the Joy and Jack Fishman Professor and Head of the Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University. Dr. Shi is the Merton Bernfield Professor of Neonatology at Boston Children’s Hospital / Harvard Medical School.

The plenary session talks will cover broad aspects of epigenetics and chromatin biology, ranging from basic molecular mechanisms to therapeutic efforts. There will be discussions around the elucidation of novel mechanisms, new tools, and other breaking topics in epigenetics and chromatin research.

About EpiCypher - A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide. EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services.

For more information about EpiCypher, visit EpiCypher.com.

Media Contact: Jim Bone, President EpiCypher, Inc. 855-374-2461

EpiCypher Introduces Nucleosome Product Line

Download PDF

FOR IMMEDIATE RELEASE: 9 July, 2015

EpiCypher™ Introduces Nucleosome Product Line Complete product line of nucleosomes allows researchers to identify authentic hits on a more consistent basis

Research Triangle Park, N.C. –July 9, 2015 – EpiCypher today announced the introduction of a complete line of purified and fully recombinant nucleosomes for use in epigenetic and chromatin biology research. Nucleosomes are the most physiologically relevant substrates for chromatin modifying enzymes and are ideal for protein binding and inhibitor screening assays in drug discovery research. EpiCypher leads the industry in both innovation and quality of nucleosome-based products.

The most compelling feature of nucleosomes from EpiCypher is the superior purity of the product (>98%), allowing more focus on optimizing libraries and reaching successful hits on a more consistent basis. “EpiCypher offers the highest quality and most highly validated nucleosome products currently available. Epigenetic proteins and enzymes are becoming increasingly important targets for therapeutic intervention. The incorporation of EpiCypher’s nucleosomes into drug development research allows researchers to identify authentic hits on a more consistent basis, as well as reducing the amount of substrate required,” states EpiCypher President Jim Bone. The stringent quality control standards utilized by EpiCypher ensure reliable and repeatable results every time, negligible lot-to-lot variation and a reduced risk of false positives or false negatives.

About EpiCypher
Pioneering the Science of Epigenetics™


A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide.

EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

Contact:
Jim Bone, President
EpiCypher, Inc.
855-374-2461

 

Blackstone Entrepreneur Network and EpiCypher collaborate

Download PDF
     
 

FOR IMMEDIATE RELEASE: 23 June 2015

Regional Entrepreneurial connector, Blackstone Entrepreneurs Network, expands in the Region with RTP Frontier space

The Blackstone Entrepreneurs Network announced its newest meeting space in The Frontier building in RTP. The Frontier, operated by the Research Triangle Foundation, is quickly becoming a hot-spot in the entrepreneurial community by providing a collaborative work environment. The move, made possible by the Research Triangle Foundation, enables the Blackstone Entrepreneurs-in-Residence (EIRs) and Companies easier access to each other and adds a central meeting place. The move will help The Network in its mission to coach high-growth companies by providing a location in the heart of the region.

The Blackstone Entrepreneurs Network was created in 2011 by a coalition of four universities (Duke, NC Central, NC State, and UNC-Chapel Hill) in conjunction with CED, and funded by the Blackstone Charitable Foundation.

 “It is fitting to add this new location in RTP to our program,” says Judith Cone, Coalition Managing Partner. “Since its founding, the RTP has been a place where academic institutions and the private sector come together to build the state’s economy. Once again the universities and private sector, through this program and this location, are collaborating toward that same goal. Unlike much of the past work that focused on recruiting industry, this program focuses on growing our own companies led by North Carolina’s proven entrepreneurs.”

According to Peter Bourne a Blackstone EIR, opening a location in RTP will enhance the program’s effectiveness. “This move will bring Network Entrepreneurs-in-Residence and Client companies into the center of the RTP startup community,” says Bourne. “The critical mass of companies and startups, and its proximity to the Triangle’s four universities, makes it an excellent strategic location.” This location will give Network Companies headquartered in Raleigh, Durham and Chapel Hill easy access to meeting space. “Having access to Research Triangle Park is a huge advantage for us,” says Jim Bone, President and co-founder of EpiCypher, a Mentored Network company. “We’re able to meet with our Blackstone EIRs at the Park and make connections that would not be possible sitting in our office.”

The Frontier is the first project in the new Park Center development and is designed as an open community space for those located in and aroud the Research Triangle Park. The Frontier provides free work and meeting space, as well as competitive lease rates for private offices throughout the 142,000 square foot building.

“We are thrilled to have Blackstone Entrepreneurs Network in The Frontier,” said RTP Chief Operating Officer Mason Ailstock. “The Network is an amazing resource for entrepreneurs and startups in the region, and their presence is a valuable addition to our growing list of tenants. We’re excited for the many opportunities this partnership will bring RTP,” said Ailstock.

About Blackstone Entrepreneurs Network: The Blackstone Entrepreneurs Network mission is to unlock the tremendous economic potential of startups from the universities and the community in the RTP region and the State of North Carolina. Proven, serial entrepreneurs (EIRs), who have themselves raised significant venture capital, work together as a cohesive group to provide intensive coaching to promising entrepreneurial teams. Their goal is to help the next generation of entrepreneurial ventures raise the capital necessary to reach their next stages of growth. This is a philanthropic endeavor free of charge to those accepted in the program and takes no equity in the companies it coaches. To learn more, visit www.blackstoneentrepreneursnetwork.org.

About The Research Triangle Park The Research Triangle Foundation of North Carolina serves the Research Triangle Park, a bellwether institution that was once referred to by Governor Luther Hodges as the “heart and hope of North Carolina.” Situated centrally among Duke University, North Carolina State University and the University of North Carolina at Chapel Hill, RTP contains 7,000 acres, 50,000+ employees, and over 200 companies, including Avaya, Cisco, Credit Suisse, IBM, NetApp, RTI International and Syngenta. RTP is also home to The Lab, an affordable incubation space for entrepreneurs and startups.

About The Frontier Located in the heart of RTP’s Park Center development, The Frontier is an open collaboration destination that can be used by anyone in the community for a variety of reasons. It’s connected to lightning fast internet, has free Counter Culture coffee for all visitors and plays host to weekly events sponsored by The Research Triangle Park. There’s never any shortage of activity, and the community at-large is invited to use the space as if it was their very own. Find out more at rtp.org/thefrontier.

About EpiCypher Pioneering the Science of Epigenetics™ A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide.

EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

Contact information: Sheryl Waddell Email address: Sheryl.waddell@BlackstoneEN.org Phone Number: 610-573-3211

EpiCypher Launches New Website and New Identity

Download PDF
     
 

FOR IMMEDIATE RELEASE: 17 February, 2015

EpiCypher Launches New Website and New Identity
Users find extensive resources, an enhanced user experience, and rich content at www.epicypher.com.

Research Triangle Park, N.C. –February 17, 2015 – EpiCypher today announced the launch of a new version of www.epicypher.com. Key benefits of the new site include a cleaner & more attractive design, a more engaging user experience with enhanced search, improved navigation and deeper e-commerce capabilities. The new online presence provides fast and intuitive access to the company’s deep product lines as well as extensive resources for scientists with demanding needs in epigenetic and chromatin biology.

The website was created with the user experience firmly in mind. For mobile applications in particular, the site delivers an excellent user experience using the latest technology. The site’s refreshed & simplified look, enhanced content, improved search functionality, and optimization for mobile devices allows visitors to immerse themselves in the depth of EpiCyphers capability.

Our mission is to connect scientist and researchers to the latest in epigenetic tools, products and services. “The science-centric design of the site provides an innovative platform for researchers that will boost the applicability of our products and services to researchers needs, and thus further their discoveries,” says EpiCypher president and co-founder, Jim Bone.

 

About EpiCypher Pioneering the Science of Epigenetics™

A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide.

EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

 

Contacts: Jim Bone, President EpiCypher, Inc. 855-374-2461

EpiCypher announces epigentics grant program award winners

Download PDF
     
 

FOR IMMEDIATE RELEASE: 7 October 2014

EpiCypher™ Awards Five Epigenetic Research Grants EpiCypher’s First Annual Grant Program Funds 5 Histone Modification Research Projects

Chapel Hill, N.C. –October 7, 2014 – EpiCypher announces the award of five grants for Histone Peptide Array Screening Services to researchers at Indiana University, Memorial Sloan Kettering Cancer Center, The University of Florida, The University of Montreal and The Structural Genomics Consortium as part of their first annual grant program in support of chromatin biology and epigenetics research. The scientific founders of EpiCypher reviewed each grant application and selected the winners, each of whom will receive histone modification screening services employing EpiCypher’s world-class EpiTitan™ Histone Peptide Arrays, along with a statistical analysis of their protein’s or antibody’s histone modification binding profile.

The grantees are: Levi Blazer, Ph.D., Structural Genomics Consortium; El Bachir Affar, Ph.D., University of Montreal; Omar Abdel-Wahab, M.D., Memorial Sloan-Kettering Cancer Center; Feng-Chun Yang, Ph.D., Indiana University School of Medicine; and Daiqing Liao, Ph.D, University of Florida. The grant recipients and their respective organizations will work individually but collaboratively with EpiCypher’s scientific team to help answer each project’s fundamental biological question.

EpiCypher is dedicated to giving researchers access to the highest quality, most productive approaches for more meaningful investigations into chromatin biology and epigenetics research. “We look forward to introducing these winners to the many benefits of our transformative products and incorporating them into their research so they can experience their advantages to chromatin research first hand,” says EpiCypher President and co-founder Jim Bone.

 

About EpiCypher Pioneering the Science of Epigenetics™

A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers worldwide.

EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

 

Contacts: Jim Bone, President EpiCypher, Inc. 855-374-2461

EpiCypher Announces Next-Generation Histone Peptide Array

Download PDF
     
 

FOR IMMEDIATE RELEASE: 3 September 2014

EpiCypher Announces Next-Generation Histone Peptide Array

EpiTitan™ to replace first-generation EpiGold™ Array

Chapel Hill, N.C. – August 25, 2014 – EpiCypher, a pioneer in the field of epigenetics and chromatin biology, announced today the introduction of its next-generation Histone Peptide Array – EpiTitan™. The platform was designed for rapid, high-throughput screening of effector protein interaction, antibody binding and enzyme activity. The peptides on the array encompass over 95 unique modifications on the four core histones along with several histone variants – the most available of any platform on the market.

“EpiTitan is a significant improvement over our previous platform,” said Jim Bone, President and co-founder of EpiCypher. “Some of the improvements include the capability to perform multiple experiments per array, 20 additional peptides, the ability to run two samples on one array, a significantly increased number of modifications, as well as enhanced scanning and analysis tools. This new platform will provide our customers with conclusions at critical phases of research with significantly reduced errors arising from other peptide array platforms. It also includes our patent-pending peptide spotting tracer, which significantly increases the believability of the data by reducing false negatives”.

The EpiTitan™ arrays can be used to examine the selectivity and specificity of histone modification antibodies, analyze the specificity of histone binding proteins and identify substrates of histone modifying enzymes.

About EpiCypher Pioneering the Science of Epigenetics™. A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers world-wide. EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells purified and recombinant nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

Contact: Jim Bone, President EpiCypher, Inc. 855-374-2461

EpiCypher announces grant program for epigenetics research

Download PDF

EpiCypher™ Announces Epigenetic Grant Program

EpiCypher to offer five grants to researchers for histone peptide array applications that have significant impact on epigenetics research and development.

Chapel Hill, N.C. – July 1, 2014 – As part of the company’s continuing efforts to help researchers unlock biological mysteries, EpiCypher today announced they are offering five (5) fully-funded Epigenetic Grants. The company will fund projects that involve the study of the role of histone modifications in physiologic or pathologic processes. For the studies selected, EpiCypher will provide EpiTitan™ histone peptide arrays, histone modification screening services and statistical analysis of protein or antibody binding profile.

Epigenetics is the study of heritable changes in phenotype that exhibit no underlying changes in DNA sequence. Over the past several years there has been a significant increase in the number of epigenetic regulators as clinical targets, including Histone Deacetylases (HDACs), Bromodomain Proteins (BET), and histone methyltransferases including DOT1L and EZH2. A number of these targets have FDA-approved drugs, or are in late stage clinical trials, to inhibit their function, demonstrating the adoption of supporting patients with diseases involving epigenetic targets.

“Understanding fundamental questions at the molecular level are one of the most exciting and important frontiers in biomedical science, and many answers will be found through the study of chromatin biology and epigenetics. The goal of these grants is to introduce researchers to the benefits of epigenetics and to incorporate this method into their research so they can experience its biological advantages first hand,” said Jim Bone, President and co-founder of EpiCypher. “Projects should speak to the public health importance, the significance of the application and/or any clinical potential.”

Applications for the grant are due by September 10, 2014 and the awardees will be notified no later than September 29, 2014. For more information about the program, including application requirements and materials, visitwww.epicypher.com/grant.aspx.

 

EpiCypher announces Sam Tetlow as CEO and relocation to North Carolina

Download PDF
     
 

FOR IMMEDIATE RELEASE: 25 June 2014

EpiCypher announces Sam Tetlow as Chief Executive Officer and Company relocation to North Carolina

EpiCypher's vision of leading the epigenetics field is further enabled by Sam joining the company and its relocation to Chapel Hill, a well recognized center of excellence for epigenetics.

Chapel Hill, N.C. – June 25, 2014 – EpiCypher today announced that Sam Tetlow has been named Chief Executive Officer and a member of the Board of Directors. Both roles were previously not filled. EpiCypher will officially move the Company to North Carolina to undertake R&D and lab operations in Chapel Hill, NC. The Company also announces it has been accepted as part of the Blackstone Entrepreneurs Network.

"We are thrilled Sam has joined our team! We look forward to him leading the organization as we develop our differentiated portfolio of epigenetic products and help researchers achieve unprecedented results by using our products," said Scientific Founders Mark Bedford Ph.D., Or Gozani, M.D. Ph.D., and Brian Strahl, Ph.D., in a joint statement. "Sam has already had an impact on customer adoption of our products and in realizing our strategic goals for 2014 and beyond. EpiCypher's vision is to lead the epigenetics field to improve human health and Sam joining is an important step in realizing that vision."

Sam joins Dr. Jim Bone, President and COO and Dr. Zu-Wen Sun, Chief Scientific Officer on the management team. Sam has a strong track record as a catalyst for growth of early-and-mid stage services, drug development, and medical technology companies in both management and investor roles. His experience includes leading organic growth, partnership development, strategic planning and company leadership.

Most recently Sam was CBO with ILS, where he led organic growth in the commercial sectors and launched ILS Genomics, following the purchase of Beckman Coulter Genomics. Sam was the General Manager of ILS Genomics, leading the Company from launch through its first full year of operations. Prior to that, Sam was a lead director with Immunologix, a Medical University of South Carolina spinout that was launched, built and sold for a 10x return for investors within a 24-month period. Prior to that, Sam was a full time Partner with Research Triangle Ventures, where he led the full cycle of life science investing which included serving as Executive Chairman of Gentris Corporation as well as managing the firm's investment in Tranzyme Pharma, among others. Sam has a Bachelor's of Science from Worcester Polytechnic Institute (honors) and a MBA from UNC Kenan-Flagler Business School (honors).

 

EpiCypher and tebu-bio announce European partnership to distribute industry leading epigenetic products

Download PDF
     
 

FOR IMMEDIATE RELEASE: 28 January 2014

EpiCypher and tebu-bio announce European partnership to distribute industry leading epigenetic products.

The pan-European partnership creates a strong combination of the highest quality, innovative products from EpiCypher and the scientific-based relationships of tebu-bio.

RESEARCH TRIANGLE PARK, N.C. – January 28, 2014 – EpiCypher has selected tebu-bio of Le Perray, France to bring European researchers access to EpiCypher’s proprietary products for epigenetics and chromatin biology research. Tebu-bio’s network of local offices in Belgium, France, Germany, Italy, The Netherlands, Denmark, Finland, Norway, Sweden, Portugal, Spain and the U.K. is one of the largest in the European discovery research markets.

Researchers in Europe have a tremendous need for quality products and tebu-bio is a valuable partner to support them. Tebu-bio has supplied European researchers with a diverse portfolio of life science reagents and lab services since 1953. Their commitment to reliable, high quality products is recognized in the market.

“Our partnership with tebu-bio supports our continued commitment to our customers’ success” stated Jim Bone, President of EpiCypher. “During in-person discussions in Europe with tebu-bio, the opportunity to realize our mutual success became clear. As epigenetics continues to gain importance in the global research field, this partnership will increase our presence in the global market to meet demand and further aid the realization of EpiCypher’s business strategy.”

"EpiCypher's portfolio will perfectly complement tebu-bio's offering in the emerging field of epigenetics. On one hand we will explore a new market with EpiCypher's Histone Peptide Arrays: hundreds of highly purified histone derived peptides - unmodified and modified and spotted to the array - allowing in-depth interaction studies”, said Dr. Ali el Baya, tebu-bio Sales Manager for Proteins & Protein based Products & Services. “EpiCypher's native and recombinant nucleosome preparations and epigenetic enzymes will enlarge our offer for screening activities especially in the Drug Discovery environment."

EpiCypher develops and manufacturers novel tools for epigenetics and chromatin biology research, based on the expertise of their industry-leading scientific team. Our founders are renowned chromatin researchers, whose knowledge, experience and unique insight into epigenetics benefits our customers in ways that other companies cannot duplicate.  

To find out more about EpiCypher’s products available from tebu-bio, visit tebu-bio's website.

CDI Laboratories and EpiCypher Form Alliance to Develop Monoclonal Antibodies for Epigenetics Research

Download PDF
     
 
Press Release - May 30, 2013
 
CDI Laboratories and EpiCypher Form Alliance to Develop Monoclonal Antibodies for Epigenetics Research
 
CDI Laboratories (Mayaguez, Puerto Rico) and EpiCypher, Inc (The Woodlands, TX) have signed an agreement to collaborate on the development of monoclonal antibodies for epigenetics and chromatin biology research. Epigenetics is the study of stable changes in cell function and identity that occur without alterations in DNA sequence. 
 
The project will utilize CDI’s Fast-MAb® monoclonal antibody development technology and EpiCypher’s patented EpiGold™ Histone Peptide Arrays to develop novel antibodies against histone modifications. Histone modifications are important mediators of epigenetic phenomena, and antibodies to histone modifications are valuable tools in epigenetics research.
 
“CDI has a terrific setup to develop monoclonal antibodies. Their Fast-MAb® system is a perfect fit with our EpiGold™ Histone Peptide Arrays,” stated EpiCypher president Jim Bone. “EpiCypher’s histone peptide array platform allows us to identify antibodies specific for histone modifications quickly and easily,” according to CDI vice president and head of business development Scott Paschke. “We are looking forward to a lot of great histone antibodies this year.” 
 
About CDI Laboratories: CDI Laboratories, Inc. (CDI) is a biotechnology company that delivers products and services founded on whole human proteome microarray technology as well as monoclonal antibody production. CDI’s antibodies are tested using its whole human proteome microarray technology, which provides unsurpassed specificity. The company’s products and services overcome great hurdles that are currently slowing down advancements in the proteomics field in the areas of research, and protein-based therapeutics and diagnostics.